In consultation: Guidance and quality standards

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Consultation end date

Consultation end date

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 11 to 17 of 17

TitleConsultationTypeConsultation end date
Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors (review of TA881) [ID6496]Final draft guidanceTechnology appraisal guidance
Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407]Final draft guidanceTechnology appraisal guidance
Norucholic acid for treating primary sclerosing cholangitis [ID6583]Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Pegcetacoplan for treating complement 3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489]Draft guidanceTechnology appraisal guidance
Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia [ID6232]Draft guidanceTechnology appraisal guidance
Bepirovirsen for treating chronic hepatitis B [ID6608]Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Rebisufligene etisparvovec for treating mucopolysaccharidosis type IIIA [ID6540]Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All